Hyperion Therapeutics, Inc. announced that it has completed patient enrollment in its Phase 1/2 clinical trial to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 (formally called GT4P) versus BUPHENYL(R) (sodium phenylbutyrate) in patients with urea cycle disorders (UCD). The company plans to announce top-line results in the fourth quarter of this year.

More: continued here

This entry was posted on Saturday, July 26th, 2008 at 12:07 am and is filed under Clinical Trials. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.